{"title":"过敏性反应治疗的进展:鼻内和舌下与肌内肾上腺素。","authors":"Jay Adam Lieberman, Matthew Greenhawt","doi":"10.1097/ACI.0000000000001089","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Epinephrine is universally considered the standard of care for the treatment of severe allergic reactions, including anaphylaxis, and, until recently, was preferentially recommended to be given intramuscularly in the thigh. However, newer routes of administration have been studied, with the intranasal route recently approved by regulatory agencies.</p><p><strong>Recent findings: </strong>Pharmacokinetic and pharmacodynamic studies suggest that noninjectable epinephrine routes (e.g., intranasal and sublingual) can achieve epinephrine levels on par with intramuscular administration via autoinjector.</p><p><strong>Summary: </strong>With new routes of epinephrine delivery being studied and approved for use, a new frontier of anaphylaxis management is emerging. There is potential that these routes may change how epinephrine is administered and severe reactions, including anaphylaxis, are treated.</p>","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":"309-314"},"PeriodicalIF":2.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advances in the treatment of anaphylaxis: intranasal and sublingual versus intramuscular epinephrine.\",\"authors\":\"Jay Adam Lieberman, Matthew Greenhawt\",\"doi\":\"10.1097/ACI.0000000000001089\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>Epinephrine is universally considered the standard of care for the treatment of severe allergic reactions, including anaphylaxis, and, until recently, was preferentially recommended to be given intramuscularly in the thigh. However, newer routes of administration have been studied, with the intranasal route recently approved by regulatory agencies.</p><p><strong>Recent findings: </strong>Pharmacokinetic and pharmacodynamic studies suggest that noninjectable epinephrine routes (e.g., intranasal and sublingual) can achieve epinephrine levels on par with intramuscular administration via autoinjector.</p><p><strong>Summary: </strong>With new routes of epinephrine delivery being studied and approved for use, a new frontier of anaphylaxis management is emerging. There is potential that these routes may change how epinephrine is administered and severe reactions, including anaphylaxis, are treated.</p>\",\"PeriodicalId\":10956,\"journal\":{\"name\":\"Current Opinion in Allergy and Clinical Immunology\",\"volume\":\" \",\"pages\":\"309-314\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Allergy and Clinical Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/ACI.0000000000001089\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Allergy and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ACI.0000000000001089","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
Advances in the treatment of anaphylaxis: intranasal and sublingual versus intramuscular epinephrine.
Purpose of review: Epinephrine is universally considered the standard of care for the treatment of severe allergic reactions, including anaphylaxis, and, until recently, was preferentially recommended to be given intramuscularly in the thigh. However, newer routes of administration have been studied, with the intranasal route recently approved by regulatory agencies.
Recent findings: Pharmacokinetic and pharmacodynamic studies suggest that noninjectable epinephrine routes (e.g., intranasal and sublingual) can achieve epinephrine levels on par with intramuscular administration via autoinjector.
Summary: With new routes of epinephrine delivery being studied and approved for use, a new frontier of anaphylaxis management is emerging. There is potential that these routes may change how epinephrine is administered and severe reactions, including anaphylaxis, are treated.
期刊介绍:
This reader-friendly, bimonthly resource provides a powerful, broad-based perspective on the most important advances from throughout the world literature. Featuring renowned guest editors and focusing exclusively on one to three topics, every issue of Current Opinion in Allergy and Clinical Immunology delivers unvarnished, expert assessments of developments from the previous year. Insightful editorials and on-the-mark invited reviews cover key subjects such as upper airway disease; mechanisms of allergy and adult asthma; paediatric asthma and development of atopy; food and drug allergies; and immunotherapy.